Advertisements

Apo-Glyburide

Quick links to important sections

Apo-Glyburide

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Apo-Glyburide

Property Description
Active ingredient Glibenclamide (Glyburide)
Form Tablet (Solid dosage form)
Pharmacological class Sulfonylurea antidiabetic agent
Common use Blood glucose control in Type 2 diabetes
Origin Synthetic compound

Defining the Drug Entity and Its Ingredient

Apo-Glyburide is a prescription-only oral medication supplied as a tablet, whose active ingredient is Glibenclamide (synonym: Glyburide), a synthetic chemical compound. The "Apo" prefix often indicates that this specific preparation is distributed by Apotex Corporation, distinguishing it from other formulations of the drug. This is a single-ingredient product, confining its pharmacological effect solely to Glibenclamide, which belongs to the sulfonylurea chemical class.


Apo-Glyburide's Pharmacological Class and Type

Apo-Glyburide is classified as an antidiabetic agent, specifically functioning as a second-generation sulfonylurea and an oral hypoglycemic agent (OHA). This designation confirms its role as an insulin secretagogue, meaning its primary action is to stimulate the release of stored insulin from the specialized beta cells in the pancreas. This mechanism is utilized for promoting insulin secretion, making the drug a standard therapeutic option for adults requiring assistance with endogenous insulin mobilization.


General Purpose: Controlling Blood Sugar Levels

Its fundamental purpose is to establish and maintain metabolic control over chronic hyperglycemia (high blood sugar), the characteristic feature of type 2 diabetes mellitus. By prompting the required insulin response, the drug provides essential support for long-term chronic management. The use of sulfonylureas, such as Glibenclamide, is a recognized strategy for achieving glycemic targets. Its typical use involves its prescribed addition to a patient's routine to provide reliable, consistent blood glucose reduction.

Advertisements

What side effects are possible with Apo-Glyburide?

Possible Side Effects and Safety Information

The safety profile of Apo-Glyburide (Glibenclamide) is officially documented by regulatory authorities, with adverse reactions categorized by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most defining risk is hypoglycemia (abnormally low blood sugar), which is classified as a Common adverse reaction in regulatory documents, consistent with the sulfonylurea drug class. Other effects, like gastrointestinal disturbances (e.g., nausea, diarrhea) and allergic skin reactions, are also classified as Common.

Less frequent events are classified as Uncommon (e.g., elevated liver enzymes, cholestatic jaundice) or Rare (e.g., certain blood dyscrasias like leukopenia or thrombocytopenia). Severe, very rare reactions include conditions such as Stevens-Johnson Syndrome and agranulocytosis.

System-Organ Classes and Serious Reactions

Adverse reactions are formally grouped into system-organ classes, including Metabolism and Nutrition Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.

The label explicitly lists Severe Hypoglycemia as a serious adverse reaction due to the potential for significant neurological consequences. Severe blood disorders and severe hepatic dysfunction are also documented as serious, rare risks.

Safety Considerations and Constraints

Official labeling notes that the risk of hypoglycemia is highest during treatment initiation or dose escalation. Specific patient populations are noted to have increased susceptibility to hypoglycemia, including older adults and individuals with severe renal or hepatic impairment. The medication is officially contraindicated in cases of known hypersensitivity to Glibenclamide or other sulfonamide derivatives, or in individuals with severe kidney or liver insufficiency.

Advertisements

Overdose and Emergency Response

Apo-Glyburide Overdose and when to seek help

The official regulatory profile for Glibenclamide (Apo-Glyburide) overdose centers on the risk of severe and prolonged hypoglycaemia, which is officially classified as a life-threatening medical emergency.

Overdose manifestations documented in official labeling include signs of neuroglycopenia such as confusion, stupor, and visual disorders, often accompanied by autonomic symptoms like sweating, tremor, and rapid heartbeat. Severe outcomes may escalate to seizures and coma, carrying the documented risk of permanent neurological damage if left uncorrected.

Immediate medical attention is required for any suspected overdose or when severe clinical signs are present. Regulators mandate prompt hospitalization to manage the reaction. Supportive procedures described in labeling include the necessary administration of intravenous dextrose/glucose for severe episodes and may involve the use of activated charcoal to limit absorption.

Crucially, prolonged hospital monitoring for 24 hours or more is specified as necessary due to the high risk of recurrent hypoglycemia following initial stabilization. The regulatory documents note increased susceptibility to severe effects in elderly patients and individuals with renal impairment due to altered drug clearance.

Advertisements

Therapeutic Uses of Apo-Glyburide

What Apo-Glyburide Treats: Main Uses and Benefits

Apo-Glyburide is commonly used in the treatment strategy for the long-term chronic management of Type 2 Diabetes Mellitus in adults. The medication is applied along with diet and exercise to address the systemic imbalance of chronic hyperglycemia—the state where blood sugar remains persistently elevated despite foundational lifestyle adjustments. The medication is applied across therapeutic domains to help manage conditions of inadequate glycemic control. Its clinical relevance involves managing chronic high blood sugar, contributing to overall metabolic control, and assisting in achieving established glycemic targets.


This treatment is considered relevant when supportive symptom management is appropriate, particularly in clinical settings where dedicated pharmacological support is commonly used to assist in sustaining systemic stability. A key therapeutic benefit involves support for a sustained reduction of plasma glucose levels, which helps the adult patient in achieving and maintaining therapeutic glycemic targets set by their healthcare team. As a patient-oriented benefit, this supports general long-term well-being and helps ease the overall burden of the condition.

“The medication may assist patients in coping more steadily with the symptom fluctuations inherent in the condition.”

Quick Fact: Support for Inadequate Glycemic Control

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Apo-Glyburide

Official regulatory information defines the appropriate patient population for Apo-Glyburide (Glibenclamide), restricting its use primarily to adult patients with Type 2 Diabetes Mellitus. This medicine is contraindicated and must not be used by several specific patient groups.


Absolute Contraindications

Contraindicated Populations Condition-Specific Contraindications
Patients with Type 1 Diabetes Mellitus Diabetic Ketoacidosis or diabetic coma/precoma
Known hypersensitivity to Glibenclamide, other sulfonylureas, or sulfonamides Severe renal impairment or severe hepatic impairment (frank jaundice)
Patients concurrently using Bosentan Use during pregnancy and lactation

Restricted and Non-Recommended Use

Age-Group Limitations Condition-Specific Restrictions
Pediatric patients (under 18 years): Safety and effectiveness are not established; use is not recommended Use must be discontinued during periods of acute stress (e.g., severe infection, surgery)
Older adults (Geriatrics): Require special caution due to increased susceptibility to hypoglycemia Conditional use with caution in mild to moderate renal or hepatic impairment

Eligibility rules are strictly defined by regulatory documents, and use outside the approved adult population or in the presence of a contraindication is prohibited.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify documented interaction patterns for Glibenclamide based on their effect on blood glucose control or drug exposure.

Formal Contraindications

Co-administration of Glibenclamide is strictly contraindicated with Bosentan due to a documented risk of elevated liver enzymes. Systemic or oromucosal Miconazole is also prohibited in some regulatory labels due to the potential for severe, prolonged low blood sugar.

Pharmacodynamic and Exposure-Altering Interactions

Interaction Classification Examples of Interacting Substances
Potentiation of Hypoglycemia (Increased Effect) Nonsteroidal Anti-inflammatory Agents (NSAIDs), Salicylates, Sulfonamides, ACE Inhibitors, Probenecid, MAOIs (Monoamine Oxidase Inhibitors). Many potentiating agents act by displacing Glibenclamide from its protein binding sites.
Antagonism of Glycemic Control (Weakened Effect) Thiazide Diuretics, Corticosteroids, Estrogens and Oral Contraceptives, Phenytoin, Rifampin, and Thyroid Products.

Beta-Blockers are officially noted as potentially reducing or masking the body’s warning signs of low blood sugar. Alcohol is documented to have an unpredictable effect, capable of either potentiating or weakening the glucose-lowering action. Severe renal or hepatic insufficiency is noted to increase the risk of serious hypoglycemic interactions due to elevated Glibenclamide exposure.

Advertisements

Mechanism of Action

Apo-Glyburide acts by binding directly to the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive potassium channel (KATP channel) on the pancreatic beta cell . This interaction causes the channel to block the efflux of K^+ ions. This primary molecular action shifts the beta cell's electrical potential, causing the cell membrane to depolarize.

The resulting membrane depolarization acts as the required signal to open voltage-dependent Ca^2+ channels, initiating a rapid influx of Ca^2+ ions into the cell. The increased intracellular Ca^2+ concentration then functions as the key physiological signal that promotes the immediate release of pre-synthesized endogenous insulin stored in the beta-cell vesicles (exocytosis).

The secretion of insulin is the systemic consequence of the drug's mechanism, and this hormone then acts on peripheral tissues (like muscle and adipose) and the liver. Insulin increases glucose transport from the bloodstream into peripheral cells while simultaneously suppressing the liver's release of glucose (gluconeogenesis). This dual effect on clearance and production is the resulting physiological modulation.

Advertisements

Dosage and Administration Information

Official Instructions for Using Apo-Glyburide

Apo-Glyburide (Glibenclamide) is administered only via the oral route as a tablet. Its usage protocol is strictly defined concerning dosage, timing, and patient-specific adjustments, and it is intended for long-term chronic management.


Administration Protocol

Instruction Official Guideline
Route of Administration Oral.
Timing with Meals Must be taken with breakfast or the first main meal of the day.
Dosing Frequency Typically administered once daily. Doses exceeding 10 mg (standard) or 6 mg (micronized) may be divided into two administrations daily.
Missed Dose Rule A double dose must not be taken to compensate for a forgotten dose.

Dosage and Adjustments

The starting dose for the standard tablet formulation is typically 2.5 mg to 5 mg once daily. The standard dose is increased in increments of no more than 2.5 mg, which occurs at weekly intervals based on glucose response. The maximum recommended daily dose for the standard tablet formulation is 20 mg.

For the micronized tablet formulation, the initial dose is generally 1.5 mg to 3 mg once daily, with a maximum daily dose of 12 mg. The two tablet formulations are not interchangeable at the same strength, requiring full re-titration if switching.

Population-Specific Rules and Constraints

In populations with increased sensitivity, such as older adults or those with mild-to-moderate renal or hepatic impairment, treatment is initiated with the lowest available dose, such as 1.25 mg. Furthermore, when co-administering Colesevelam, Apo-Glyburide must be taken at least 4 hours prior to the Colesevelam dose to ensure proper absorption.

These official guidelines establish the precise conditions for initial use and subsequent long-term management, standardizing the procedural pattern for using the medication.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Safety Assessment

Research has explored the effects of the compound on symptoms associated with Condition X in individuals experiencing acute episodes. Studies evaluated whether the compound was associated with changes in quality of life metrics and assessed the frequency of flare-ups over a 12-week course.

  • Symptom Scoring: Studies recorded the time to initial observed change.
  • Quality of Life: Researchers analyzed data on patient-reported quality of life metrics.
  • Flare-Up Frequency: The frequency of recurrence was monitored and reported throughout the 12-week observation period.

Comparative Research: Monotherapy vs. Combination Therapy

Research has compared the outcomes associated with combination therapy to those of monotherapy.

  • Observed Effects: In these studies, researchers observed the effect on reported pain levels and measures of inflammation. They also assessed the duration of recovery periods.
  • Study Completion: The studies assessed the outcomes associated with completing the full duration of the course.

Safety and Tolerability Profile

The research examined the safety profile of the treatment.

  • Adverse Events: Data from the trials tracked and reported common and serious adverse events across all study groups.
  • Specific Populations: The research excluded or noted specific caution for participants with pre-existing kidney conditions. One study assessed the potential for symptom management over an extended period.

Summary of Outcomes

The evidence gathered from these studies describes the observed outcomes and adverse events associated with the compound's use in the studied population. It is not yet clear whether these results generalize to all populations or reflect individual clinical suitability.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo-Glyburide (FAQ)


Q: How long does the effect of Apo-Glyburide last in the body?

Official information describes the active ingredient in Apo-Glyburide as a long-acting sulfonylurea, which supports its usual once-daily administration. Research notes that the half-life of the active ingredient is prolonged, which supports this dosing, though individual elimination rates can vary.


Q: Is Apo-Glyburide the same as Glipizide or Glimepiride?

No, they are distinct medications. Apo-Glyburide is in the same class of medicines, called sulfonylureas, as Glipizide and Glimepiride. They all work in a similar way to help control blood sugar, but official documents describe them as having their own unique active ingredients and properties.


Q: Can Apo-Glyburide affect my weight?

Studies examining the active ingredient in Apo-Glyburide have reported weight gain as a possible effect. However, the topic of weight change is not uniformly classified as a common or uncommon side effect across all official regulatory drug labels.


Q: What happens if you accidentally miss a dose of Apo-Glyburide?

Official patient instructions strictly state that you must not take a double dose to make up for a forgotten dose. Due to the risk of low blood sugar, guidance on handling a missed dose is determined by a healthcare provider.


Q: What types of heart issues might make taking Apo-Glyburide risky?

Regulatory documents advise that caution is needed for patients who have existing heart disease. Official sources have noted that caution is advised regarding a potential increase in cardiovascular risk associated with the sulfonylurea class of medications.


Q: What should I do if my blood sugar stays high while taking Apo-Glyburide?

A loss of blood sugar control can sometimes occur when a person experiences physical stress, such as severe infection or fever. If blood sugar remains high (hyperglycemia), it is important that a person's healthcare provider or diabetes educator is informed.


Q: What are some reasons why Apo-Glyburide might stop working for someone?

Official drug labels acknowledge that sometimes the drug may stop working over time, a condition referred to as secondary failure. This loss of effectiveness may occur due to the progression of Type 2 diabetes or the body becoming less responsive to the drug's action.


Q: Can I take pain relievers like Ibuprofen or Tylenol with Apo-Glyburide?

Official documents note that nonsteroidal anti-inflammatory agents (NSAIDs), such as Ibuprofen, can increase the risk of low blood sugar. Interactions with other medicines must be reviewed with a health professional before taking any other product, including over-the-counter items like Acetaminophen (Tylenol).


Q: Why do some official sources mention Apo-Glyburide's effect on the pancreas?

Official documentation describes Apo-Glyburide as an insulin secretagogue. This means the drug's intended action is to directly stimulate the pancreas to release insulin. This specific action is why the pancreas is mentioned prominently in the description of the drug's mechanism.


Q: Is Apo-Glyburide an old or a new drug?

Apo-Glyburide belongs to the second-generation sulfonylurea class of antidiabetic medicines. This class was first introduced and described in official documents starting in the 1980s.


Q: What is the typical age range of people who take Apo-Glyburide?

Official drug documents indicate that Apo-Glyburide is intended only for use in adult patients with Type 2 diabetes. Its use is not recommended for individuals under 18 years of age, and older adults require special care when starting treatment.


Q: Is Apo-Glyburide known to cause any long-term side effects?

The official safety profile documents rare but serious adverse reactions, such as certain blood disorders or liver problems, that may require long-term monitoring or persistence. Hypoglycemia (low blood sugar) remains a key risk throughout treatment.


Q: Can Apo-Glyburide affect my cholesterol levels?

Studies have examined the drug’s impact on fat levels in the body. Research indicates that it may affect triglyceride levels but is not consistently associated with significant changes in total cholesterol, LDL, or HDL cholesterol levels.


Q: Is it common for people to take Apo-Glyburide with insulin?

While Apo-Glyburide is often used in combination with other oral anti-diabetic agents (like Metformin), official documents do not typically indicate its use directly with administered insulin. The drug is classified for use alone or in combination with other oral agents.


Q: What research is there on Apo-Glyburide's effectiveness?

Official documents recognize the drug as an important part of managing Type 2 diabetes, when used alongside diet, exercise, and weight reduction. Studies describe its action as an insulin secretagogue, which supports its use as an aid to achieving long-term blood sugar targets.


Q: Has Apo-Glyburide been studied in children?

Safety and effectiveness have not been established in pediatric patients (under 18 years of age) according to official drug labels. Therefore, its use is not recommended in this population.


Q: What are the signs of a serious allergic reaction to Apo-Glyburide?

Official sources document signs of a serious allergic reaction including difficulty breathing, hives, or swelling of the face, lips, tongue, or throat. Severe allergic skin reactions, such as Stevens-Johnson Syndrome, are also possible.


Q: Can Apo-Glyburide be taken with blood pressure medication?

Official documents list certain classes of blood pressure medicines as interacting substances. ACE Inhibitors may increase the drug's effect, while Thiazide Diuretics may weaken it. Reviewing all combination use with a health professional is necessary.


Q: Is it safe to drive or operate machinery while taking Apo-Glyburide?

Official patient information notes that a person’s alertness may be impaired due to episodes of high or low blood sugar. This is especially true when beginning treatment, changing the dose, or taking the medication irregularly, and may affect the ability to drive or operate machinery.


Q: Does stress or illness change how Apo-Glyburide works?

Yes. Official documents state that periods of physical stress, such as severe infection, trauma, or surgery, may cause a loss of blood sugar control. In these situations, official documents note that treatment with Apo-Glyburide may need to be stopped, and temporary alternative treatments may be needed.


Q: Is there a link between Apo-Glyburide and sun sensitivity?

Official patient information indicates that an increased sensitivity to light (photosensitivity) has been reported with the use of this class of antidiabetic medicines. Precautions, such as sun protection, may be advised.


Q: What is the mechanism by which Apo-Glyburide can lead to hypoglycemia?

Apo-Glyburide is classified as an insulin secretagogue. Its main action is to force the immediate release of insulin from the pancreas. This action of releasing insulin can contribute to abnormally low blood sugar (hypoglycemia) if the blood glucose level is not high enough to match the effect.


Q: Are there specific vitamins or supplements that interact with Apo-Glyburide?

Official drug documents focus on interactions with prescription, non-prescription, and herbal products. Official labeling states that a healthcare provider must be consulted before taking any other medication, which includes vitamins or supplements.


Q: Is Apo-Glyburide the first treatment option for type 2 diabetes?

Regulatory guidance emphasizes that the initial form of treatment should be non-pharmacologic (diet, exercise, and weight reduction). If these methods fail to adequately control blood sugar, then an oral sulfonylurea like Apo-Glyburide may be considered.


Q: What are the general expectations about Apo-Glyburide's impact on A1C levels?

The drug’s official purpose is to improve long-term blood sugar control. Studies report that it is associated with producing improvements in Hemoglobin A1c (HbA1c) concentrations, which is the measure used to track control over two to three months.


Q: Can Apo-Glyburide be taken if you have a sulfa allergy?

The drug is officially contraindicated (should not be used) if a person has a known allergy or hypersensitivity to Glibenclamide, other sulfonylureas, or sulfonamides. Sulfonamides are chemically related to the active ingredient.


Q: Does Apo-Glyburide interact with birth control pills?

Official product information lists Oral Contraceptives as substances that can cause antagonism of glycemic control. This means that they may lessen the blood sugar-lowering effect of Apo-Glyburide.


Q: Is Apo-Glyburide a drug that requires special precautions before surgery?

Yes. Official documents note that treatment with the drug may need to be stopped during periods of acute stress, which includes surgery or trauma. Temporary treatment changes may be required during these times.


Q: What is the recommended approach if I have stomach upset from Apo-Glyburide?

Gastrointestinal issues, like nausea or stomach upset, are classified as Common side effects. Official sources note that a person's doctor, nurse, or pharmacist should be informed if any side effect becomes severe or bothersome.


Q: Is it true that Apo-Glyburide can affect how other medications are eliminated from the body?

Interactions are known to occur between this drug and others. The primary mechanism of drug potentiation noted in official sources is the displacement of Apo-Glyburide from protein binding sites, which alters the amount of drug available in the body and its overall exposure.

Advertisements

How should Apo-Glyburide be stored and disposed of?

How to Store and Dispose of Apo-Glyburide?

The storage and disposal of Apo-Glyburide (glyburide) tablets must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Must be protected from excessive heat, moisture, and light.
Safety The medication must be kept out of the reach of children.

Disposal Instructions

No specific household disposal instructions are uniformly provided by primary regulators. Therefore, all unused or expired Apo-Glyburide tablets must be disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo-Glyburide found in:

A-Z Index: